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In transfusion centres, blood components are divided and stored following specific
guidelines. The storage temperature and time vary among the blood cells but all of
them release extracellular vesicles (EVs) under blood bank conditions. The clinical
impact of such vesicles in blood components for transfusion is an object of debate, but
should be considered and is being investigated. In this context, proteomics is an excel-
lent tool to study the cargo and composition of EVs derived from red blood cells and
platelets, since such vesicles are enriched in lipids and proteins. The development of
quantitative mass spectrometry techniques and the evolution of bioinformatics have
allowed the identification of novel EVs biomarkers for different diseases. In this con-
text, the applicationof high coverageproteomic tools to the analysis of EVs in the trans-
fusion medicine field would provide information about storage lesions and possible
transfusion adverse reactions. This viewpoint article approaches the potential of pro-
teomics to investigate the impact of EVs in blood bank transfusion components, espe-
cially red blood cells and platelets.
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1 EXTRACELLULAR VESICLES IN THE
TRANSFUSION MEDICINE FIELD
Extracellular vesicles (EVs) were depicted for the first time in 1967
when PeterWolf described them as “platelet dust” [1]. Over the years,
different studies confirmed that these small lipid particles come from
different cellular types and reflect the processes that are taking part
inside the cells. EVs are more complex than seemed at the beginning
and have been classified according to their size, biochemical compo-
sition, and cell origin [2]. The traditional nomenclature divided EVs in
three groups: exosomes, microvesicles (MV) or microparticles (MP),
and apoptotic bodies. Since consensus has not yet emerged on spe-
cific markers of EV subtypes, currently The International Society of
Extracellular Vesicles (ISEV) supports the use of the terms “small EVs”
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(<100 nm or <200 nm) and “medium/large EVs” (>200 nm) when
the origin of EVs is uncertain [2]. Nevertheless, ISEV recommends
using “extracellular vesicle” as the “generic term for particles naturally
released from the cell that are delimited by a lipid bilayer and cannot
replicate” [2].
The most interesting aspect of EVs, independently of their origin,
is their cargo. EVs cargo includes proteins, lipids, nucleic acids such
as mRNA, and other bioactive molecules. EVs participate in cell-to-cell
communication triggering an effect on the acceptor cell by the delivery
of their cargo or stimulating them via surface expression ligands. For
instance, red blood cells-derived EVs regulate nitric oxide production
under hypoxic conditions increasing vasodilation and smooth muscle
relaxation [3,4]. In addition, they also take part in redox balance [5,6]
and immunomodulation [7,8]. On the other hand, platelet-derived EVs
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participate in haemostasis and thrombosis [9], inflammation [10], and
immunity [11]. EVs are released by different cell types and are present
in many body fluids. Their analysis would permit to know about the
physiological state of the cells that release them and possible effects
onother cells. Blood is oneof the richest sources of EVsoriginated from
different cell types but the majority of those present in plasma have a
platelet origin [12].
Blood transfusion is performed nowadays as prophylaxis or treat-
ment of different clinical scenarios such as surgery, trauma, and can-
cers.Over the last century,manydiscoveries in this field have increased
the use and safety of blood products. Nowadays, transfusion centres
keep blood components separately andwith additive solutions in order
to allow extending the storage time. Each blood component has differ-
ent storage conditions. Thus, red blood cells (RBC) can be stored at
4◦C for over 42 days. On the other hand, platelets are cold-sensitive
leading to activation and, therefore, need to be stored at room temper-
ature. The high risk of the presence of growing pathogens in platelet
units led to the development of systems to inactivate them, the first
one being approved by the FDA in 2014. Currently, there are vari-
ous pathogen reduction technologies (PRT) based on the combination
of different additive solutions and wavelength light able to inactivate
a wide spectrum of viruses and bacteria. PRT consist of a compound
that intercalates between DNA strands breaking them after a radia-
tion pulse with a specific wavelength. These PRT are generally applied
to platelets units due to their absence of nucleus and their storage at
room temperature, which is not the case for instance for plasma, which
is frozen and normally stored below –20◦C (ideally at –80◦C). Differ-
ent equipment, steps to separate blood components and treatments
to avoid pathogens, have an impact on blood units leading to stor-
age lesions. In order to guarantee the safety of blood products, differ-
ent parameters and markers of storage lesion are measured in RBC,
platelets, and plasma units. In this context, EVs have started to gain
attention in the transfusion medicine field due to their role in cell-to-
cell communication and possible source of transfusion adverse reac-
tions. In fact, the measure of EVs has been recently proposed as an
internal parameter to check the quality of red cell concentrates (RCC)
and platelet concentrates (PC) during storage in blood banks [13–16].
An extended storage time of RCC for transfusion and the introduction
of PRT to improve the safety and storage time of PC have led to an
increased number of papers quantifying EVs in blood concentrates. A
selectionof themost relevant and recent ones is summarised inTable 1.
2 EVs ANALYSIS AS A SOURCE OF
BIOMARKERS OF STORAGE LESIONS
Flow cytometry (FC) is the technique most frequently used to mea-
sure EVs present in different blood concentrates. The reason for that
is the availability of flow cytometers in blood transfusion centres; how-
ever, it is important to consider many aspects related to this tech-
nique, which may have an impact on EVs quantification: the model of
flow cytometer, including the instrument settings (calibration and data
acquisition); the sample processing protocol, including washing and
staining steps; and how EVs are measured, using fluorescence mark-
ers or only light scatter. Recently, the ISEV has provided specific guide-
lines to reduce this variability [35]. Other techniques based on parti-
cle size, such as dynamic light scattering (DLS) and nanoparticle track-
ing analysis (NTA), are simple and do not require an expert technician.
However, these techniques are unsuitable for EVs quantification from
biological samples due to their poor specificity, sensitivity and dynamic
range [36]. Besides, the application of these methodologies is difficult
because it involves EVs isolation (to avoid interference with other par-
ticles present in the sample).Given the complexityof theanalysis ofEVs
mentioned above, the ISEV advises to combine different techniques to
characterise efficiently the population of EVs present in the sample.
Several papers have quantified the number of EVs present in dif-
ferent blood storage units during recent years, as indicated in Table 1.
Most of the studies evaluated how different conditions (storage (cold,
frozen, RT, DMSO), additive solutions (PAS-B/A) or blood extrac-
tion methodologies (apheresis, whole blood)) affected the number of
released EVs. Nevertheless, none of studies present in Table 1 analysed
the EVs cargo, which includes proteins, DNA, RNA, and lipids. Since the
composition of EVs is related to the cell of origin, andRBCandplatelets
do not have nucleus and genomic DNA, proteomics is an ideal tool to
study theEVs cargo and composition. Thatwould allowobtaining infor-
mation on the state of RCC and PC under storage conditions, which
could help to predict potential transfusion adverse reactions (storage
disease). Nevertheless, as indicated above, EVs contain not only pro-
teins so the combination of proteomics with the analysis of lipids and
microRNA could provide a broader overview on the state of the cell
of origin upon storage, and possible adverse effects on the recipient
patient.
3 PROTEOMIC ANALYSIS OF BLOOD
COMPONENTS IN THE TRANSFUSION MEDICINE
FIELD
In recent years, several proteomics studies of blood components, espe-
cially platelets, have increased the knowledge of storage lesions in the
transfusionmedicine field.Manyof these studies focusedon the impact
of PRT on platelets and led to the conclusion that PRT have a slighter
impact on the platelet proteome than the PC storage time [37–39].
The first proteomics analyses performed in the platelet transfusion
fieldwerebasedongel-basedmethodologies (1DE, 2DEand2D-DIGE).
As examples of the above, Prudent et al. [40] identified by 2DE mod-
ifications in DJ-1 after Intercept treatment. Marrocco et al. [41] also
identified changes in this protein, which plays a major role in antioxi-
dant stress responses in platelets following gamma irradiation. In addi-
tion, cytoskeleton proteins such as actin or gelsolin were also found
impaired with storage time and PRT by different groups [42, 43].
Recent advances in bioinformatics tools combined with MS-based
quantitative proteomics helped to identify new proteins related to
PC storage lesions. In addition to the altered proteins mentioned
above, the introduction of label free quantification (LFQ) methodolo-







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































activation, such as emilin and nidogen, among others [37, 38]. One
of the last published papers that analysed PC storage lesions by LFQ
found that many of the proteins that decrease over storage time are
localised in alpha granules and contribute to coagulation, inflammation,
and angiogenesis [37, 44]. In addition, other studies found decreasing
levels of these proteins in platelets over storage time but increasing
levels in the supernatant [45]. The latter highlights the need to anal-
yse the proteome of EVs to obtain new information about the impact
of the storage time in PC. Thus, the proteome analysis of PC-derived
EVs could help to identify biomarkers of possible transfusion adverse
reactions.
To date, there are two main studies analysing the proteome of PC-
derived EVs. On one hand, Pienimaeki-Roemer et al. [46] performed a
LFQ proteome analysis of EVs present in PC after 5 days of storage.
EVs were divided into MV and exosomes during isolation. MVs were
isolated by centrifugation applying a density gradient and exosomes
were isolated only by ultracentrifugation. It is important to point out
that this fractionation procedure is not accurate and leads to an over-
lap of different EVs subpopulations. The results showed a protein over-
lap between MV and exosomes; the protein composition was similar
in both EVs populations although with differential enrichment in each
of them. Thus, there was an enrichment of proteins such as ApoE and
Rab11 in different fractions ofMVwhereas exosomes showed a higher
expression of CD9 (typical exosomesmarker), lipid raft markers (stom-
atin, flotillin) and complement factors compared toMV.
On theotherhand, our grouphas recently analysedqualitatively and
quantitatively the proteome of PC-derived EVs after a PRT treatment
at different days of storage [47]. In this case, EVs populations were iso-
lated together by ultracentrifugation, andmany proteinswere found in
common among conditions. However, a suggested marker of platelet
storage lesion, the platelet collagen receptor Glycoprotein VI (GPVI)
[48], was only found in EVs at day 7. The quantitative analysis, based
on SWATHMS, showed an enrichment of many proteins at day 7, such
as Fructose-bisphosphate aldolase A and Triosephosphate isomerase,
enzymes related to the glycolysis pathway; and cytoskeleton proteins
related to exosome andMVshedding (CD9, actin and integrin alpha IIb,
among others). The higher expression of these proteins at day 7 of stor-
age indicates higher platelet activation levels so these proteins were
suggested as EVs-derived biomarkers of platelet storage lesion. More-
over, proteins such as C-C motif chemokine 5 (CCL5) and Platelet Fac-
tor 4 (PF4), found with higher levels at day 7 of storage, have chemoat-
tractant properties and could have an impact on the recipient after
transfusion.
Regarding the red blood cells transfusion field, it is known that
storage lesions are characterised by depletion of ATP and 2,3-
diphosphoglycerate, and a loss of red cell membrane flexibility accom-
panied by the release of EVs [49]. The study of the RBC-derived EVs to
date primarily focussed on their quantification over storage time and
the analysis of different manufacturing methods, as it is summarised in
Table 1.
In order to analyse the proteome of RBC-derived EVs, most stud-
ies were based on mass spectrometry and immunoblotting assays. In
this way, several proteins including band 3 anion transport protein,
stomatin and haemoglobin were found to be enriched in MV com-
pared to the RBC membrane [50–52]. There is a hypothesis that RBC
release EVs in storage conditions to prevent their removal from cir-
culation after transfusion when they are still functional [53]. Accord-
ing to this, EVs are a protective mechanism to allow erythrocytes to
eliminate altered proteins, lipids andothermolecules that could trigger
apoptosis [51]. This theory was reinforced by the presence of such
proteins in RBC-derived EVs [54] (e.g., membrane-bound haemoglobin,
band 3, flotillin, CD47 and inmunoglobin G), and by the identification
of specific haemoglobin oxidised residues in vesicles over storage time
[55].
In addition to the above, in recent years many publications have
analysed and confirmed the immunomodulatory and procoagulant
activity of RBC-derived EVs [8, 31, 56]. Moreover, Rhesus proteins
[50, 57] and other antigens, Kell or Lutheran [57] were also identi-
fied by FC in MV derived from RBC. Although the release of EVs from
RBC has been proposed as a protective mechanism, the discovery of
their immunomodulatory activity and the presence of antigens in their
membrane could lead to transfusion adverse reactions triggered by the
development of alloantibodies in the recipient patient. In order to elu-
cidate which explanation is the most suitable for the role of these EVs,
further comprehensive analyses of their protein cargo are needed. The
recent development of new strategies for haemoglobin depletion has
allowed to decode the proteomeofRBC in detail [58]. For this reason, it
is a goodmoment to analyse theproteomeofRBC-derivedEVsbecause
even today this is almost amystery.
4 FUTURE PERSPECTIVES AND CHALLENGES
AHEAD
Research carried out in recent years illustrates how developments
in mass spectrometry-based quantitative proteomics should be com-
bined with more precise and efficient methods to isolate pure popula-
tions of EVs to achieve a thorough analysis of EVs derived from blood
cells. In the context of the transfusion medicine field, the impact of
EVs in blood transfusion components should be explored in detail. That
should include quantifying the number of vesicles, analysing their size,
and a quantitative analysis of the EVs protein cargo (Figure 1). Detailed
functional studies should be carried out in parallel to the above.
The first proteomic studies of EVs present in blood transfusion com-
ponents, especially PC, have been already carried out, providing clues
on altered proteins related to storage lesions. Although these initial
results are promising, we should not forget the limitations we face for
this kind of studies, for example, the size of the smaller particles that
makes difficult their analysis by FC; and the low protein yield, which
requires high amounts of EVs to achieve an efficient proteomic anal-
ysis. The latter is an important issue that sometimes requires pooling
biological replicates to have enough material for a complete analysis.
And let’s not forget than in addition to the initial proteomic analysis,
further protein is needed for validations assays (e.g., immunoblotting).
Another limitation is the variety of existing protocols for the isolation
of EVs and the difficulty to obtain pure populations of EVs subtypes.
7 of 9
F IGURE 1 Schematic workflow for characterisation, quantitation, and protein identification of EVs in transfusionmedicine
In this context, and thinking in an efficient proteomic analysis, it seems
more plausible to initially analyse whole populations of EVs and focus
on subpopulations in the validation phase, when lower amounts of pro-
tein are needed. The latter is of course assuming a EVs fractionation
methodology is in place for efficient separation of subpopulations. In
line with the above, the ISEV is providing guidelines and recommen-
dations to improve the analysis of EVs with the aim of obtaining them
with a high yield and purity [2]. This is key to obtain enough material
to allow accurate proteomic analyses that can lead to the identifica-
tion of specific EVs-related biomarkers in blood components that can
be indicative of potential adverse transfusion events. In resume,we are
still in early days for this young field and, as indicated above, several
challenges lie ahead; however, the roadmap is ready and future stud-
ies should provide comprehensive data about EVs composition gener-
ated in blood banks storage conditions and their possible implications
in transfusion adverse reactions.
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F., Muşabak, U., Pekoğlu, A., Ertaş, Z., Açıkel, C., Zeybek, N., Kürekçi,
A. E., & Avcı, I. (2017). Generation of platelet microparticles after cry-
opreservation of apheresis platelet concentrates contributes to hemo-
static activity. Turkish Journal of Haematology, 34, 64–71.
28. Marcoux, G., Duchez, A. C., Rousseau, M., Lévesque, T., Boudreau, L.
H., Thibault, L., & Boilard, E. (2017). Microparticle and mitochondrial
release during extended storage of different types of platelet concen-
trates. Platelets, 28, 272–280.
29. Noulsri, E., Udomwinijsilp, P., Lerdwana, S., Chongkolwatana, V.,
& Permpikul, P. (2017). Differences in levels of platelet-derived
microparticles in platelet components prepared using the platelet rich
plasma, buffy coat, and apheresis procedures. Transfusion andApheresis
Science, 56, 135–140.
30. Waters, L., Padula, M. P., Marks, D. C., & Johnson, L. (2017). Cry-
opreserved platelets demonstrate reduced activation responses and
impaired signaling after agonist stimulation. Transfusion, 57, 2845–
2857.
31. Bouchard, B. A., Orfeo, T., Keith, H. N., Lavoie, E. M., Gissel, M., Fung,
M., & Mann, K. G. (2018). Microparticles formed during storage of red
blood cell units support thrombin generation. Journal of Trauma and
Acute Care Surgery, 84(4), 598–605.
32. Gao, M., Zhang, B., Zhang, Y., Chen, Y., Xiong, J., Wang, J., Chen, H.,
Chen, G., &Wei, Q. (2018). The effects of apheresis, storage time, and
leukofiltration on microparticle formation in apheresis platelet prod-
ucts. Transfusion, 58, 2388–2394.
33. Ghasemzadeh, M., Hosseini, E., Roudsari, Z. O., & Zadkhak, P. (2018).
Intraplatelet reactive oxygen species (ROS) correlate with the shed-
ding of adhesive receptors, microvesiculation and platelet adhesion to
collagen during storage: Does endogenous ROS generation downreg-
ulate platelet adhesive function? Thrombosis Research, 163, 153–161.
34. Oikawa, S., Minegishi, M., Endo, K., Kawashima, W., Kosunago, S.,
Oyama, M., Suzuki, K., & Shimizu, H. (2019). Impact of the platelet
washing process on in vitro platelet properties, and the levels of sol-
uble CD40 ligand and platelet-derived microparticles in the storage
media. Transfusion, 59, 1080–1089.
35. Welsh, J. A., Van Der Pol, E., Arkesteijn, G. J. A., Bremer, M., Bris-
son, A., Coumans, F., Dignat-George, F., Duggan, E., Ghiran, I., Giebel,
B., Görgens, A., Hendrix, A., Lacroix, R., Lannigan, J., Libregts, S. F. W.
M., Lozano-Andrés, E., Morales-Kastresana, A., Robert, S., De Rond, L.,
. . . Jones, J. C. (2020). MIFlowCyt-EV: A framework for standardized
reporting of extracellular vesicle flow cytometry experiments. Journal
of Extracellular Vesicles, 9, 1713526.
9 of 9
36. Welsh, J. A., van der Pol, E., Bettin, B. A., Carter, D. R. F., Jendirx, A.,
Lenassi,M., Langlois,M.A., Llorente,A., vandeNes,A. S.,Nieuwland,R.,
Tang, V., Wang, L., Witwer, K. W., & Jones, J. C. (2020). Towards defin-
ing reference materials for measuring extracellular vesicle refractive
index, epitope abundance, size and concentration. Journal of Extracellu-
lar Vesicles, 9, 1816641.
37. Rijkers, M., van den Eshof, B. L., van der Meer, P. F., van Alphen, F. P.
J., de Korte, D., Leebeek, F. W. G., Meijer, A. B., Voorberg, J., & Jansen,
A. J. G. (2017). Monitoring storage induced changes in the platelet
proteome employing label free quantitative mass spectrometry. Scien-
tific Reports, 7, 11045.
38. Salunkhe, V., De Cuyper, I. M., Papadopoulos, P., van der Meer, P.
F., Daal, B. B., Villa-Fajardo, M., de Korte, D., van den Berg, T. K., &
Gutiérrez, L. A. (2019). A comprehensive proteomics study on platelet
concentrates: Platelet proteome, storage time and Mirasol pathogen
reduction technology Platelets, 30(3), 368–379.
39. Thiele, T., Iuga, C., Janetzky, S., Schwertz, H., Gesell Salazar, M., Fürll,
B., Völker, U., Greinacher, A.,& Steil, L. (2012). Early storage lesions in
apheresis platelets are induced by the activation of the integrin αIIbβ3
and focal adhesion signaling pathways. Journal of Proteomics, 76, 297–
315.
40. Prudent, M., Crettaz, D., Delobel, J., Tissot, J. D., & Lion, N. (2012). Pro-
teomic analysis of intercept-treatedplatelets. Journal of Proteomics,76,
316–328.
41. Marrocco, C., D’Alessandro, A., Girelli, G., & Zolla, L. (2013). Proteomic
analysis of platelets treated with gamma irradiation versus a commer-
cial photochemical pathogen reduction technology. Transfusion, 53,
1808–1820.
42. Thiele, T., Steil, L., Gebhard, S., Scharf, C., Hammer, E., Brigulla, M.,
Lubenow, N., Clemetson, K. J., Völker, U., & Greinacher, A. (2007). Pro-
filing of alterations in platelet proteins during storage of platelet con-
centrates. Transfusion, 47, 1221–1233.
43. Schubert, P., Culibrk, B., Coupland, D., Scammell, K., Gyongyossy-Issa,
M., & Devine, D. V. (2012). Riboflavin and ultraviolet light treatment
potentiates vasodilator-stimulated phosphoprotein Ser-239phospho-
rylation in platelet concentrates during storage. Transfusion, 52, 397–
408.
44. Blair, P., & Flaumenhaft, R. (2009). Platelet α-granules: Basic biology
and clinical correlates. Blood Reviews, 23, 177–189.
45. Schubert, P., Culibrk, B., Karwal, S., Goodrich, R. P., & Devine, D. V.
(2016). Protein translation occurs in platelet concentrates despite
riboflavin/UV light pathogen inactivation treatment. Proteomics - Clini-
cal Applications, 10, 839–850.
46. Pienimaeki-Roemer, A., Kuhlmann, K., Böttcher, A., Konovalova, T.,
Black, A., Orsó, E., Liebisch, G., Ahrens, M., Eisenacher, M., Meyer, H.
E., & Schmitz, G. (2015). Lipidomic and proteomic characterization
of platelet extracellular vesicle subfractions from senescent platelets.
Transfusion, 55, 507–521.
47. Hermida-Nogueira, L., Barrachina, M. N., Izquierdo, I., García-Vence,
M., Lacerenza, S., Bravo, S., Castrillo, A., & García, A. (2020). Proteomic
analysis of extracellular vesicles derived from platelet concentrates
treatedwithMirasol® identifies biomarkers of platelet storage lesion.
Journal of Proteomics, 210, 103529.
48. Hosseini, E., Beshkar P., & Ghasemzadeh, M. (2018). Reverse correla-
tions of collagen-dependent platelet aggregation and adhesion with
GPVI shedding during storage Journal of Thrombosis and Thrombolysis,
46(4), 534–540.
49. Offner, P. J. (2004). Age of blood: does it make a difference? Critical
Care, 8(Suppl 2), S24–S26.
50. Rubin, O., Crettaz, D., Canellini, G., Tissot, J. D., & Lion, N. (2008).
Microparticles in stored red blood cells: An approach using flow
cytometry and proteomic tools. Vox Sanguinis, 95, 288–297.
51. Kriebardis, A. G., Antonelou, M. H., Stamoulis, K. E., Economou-
Petersen, E., Margaritis, L. H., & Papassideri, I. S. (2008). RBC-derived
vesicles during storage: Ultrastructure, protein composition, oxida-
tion, and signaling components. Transfusion, 48, 1943–1953.
52. Laurén, E., Tigistu-Sahle, F., Valkonen, S., Westberg, M., Valkeajärvi, A.,
Eronen, J., Siljander, P., Pettilä, V., Käkelä, R., Laitinen, S., & Kerkelä, E.
(2018). Phospholipid composition of packed red blood cells and that
of extracellular vesicles show a high resemblance and stability during
storage. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology
of Lipids, 1863, 1-8.
53. Solheim, B. G., Flesland, O., Seghatchian, J., & Brosstad, F. (2004). Clin-
ical implications of red blood cell and platelet storage lesions: An
overview. Transfusion and Apheresis Science, 31, 185–189.
54. Willekens, F. L., Werre, J. M., & Groenen-Döpp, Y. A. (2008). Ery-
throcyte vesiculation: A self-protective mechanism? British Journal of
Haematology, 141, 549–556.
55. Wither,M., Dzieciatkowska,M., Nemkov, T., Strop, P., D’Alessandro, A.,
&Hansen, K. C. (2016). Hemoglobin oxidation at functional amino acid
residues during routine storage of redblood cells.Transfusion,56, 421–
426.
56. Almizraq, R. J., Norris, P. J., Inglis, H., Menocha, S., Wirtz, M. R., Juffer-
mans,N., Pandey, S., Spinella, P.C., Acker, J. P., &Muszynski, J. A. (2018).
Blood manufacturing methods affect red blood cell product charac-
teristics and immunomodulatory activity. Blood Advances, 2, 2296–
2306.
57. Canellini, G., Rubin, O., Delobel, J., Crettaz, D., Lion, N., & Tissot,
J. D. (2012). Red blood cell microparticles and blood group anti-
gens: an analysis by flow cytometry Blood Transfusions, 10(Suppl 2),
s39–s45.
58. Bryk, A. H., &Wiśniewski, J. R. (2017). Quantitative analysis of human
red blood cell proteome. Journal of Proteome Research, 16, 2752–2761.
How to cite this article: Hermida-Nogueira L, García Á.
Viewpoint: Extracellular vesicles in the transfusionmedicine
field: The potential of proteomics. Proteomics.
2021;21:e2000089. https://doi.org/10.1002/pmic.202000089
